Employees: 11 (2023.0)Legal category: 5785Size: PMECreation date: 2002-04-01 (24 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: CHASSE-SUR-RHONE (38670), Isere
PHARMACIE LUANGKHOT : revenue, balance sheet and financial ratios
PHARMACIE LUANGKHOT is a French company
founded 24 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in CHASSE-SUR-RHONE (38670),
this company of category PME
shows in 2023 a revenue of 2.2 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE LUANGKHOT (SIREN 442078366)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
2 164 763 €
N/C
N/C
1 925 699 €
N/C
N/C
N/C
Net income
77 961 €
63 568 €
108 999 €
154 502 €
115 069 €
32 627 €
22 960 €
42 171 €
32 988 €
EBITDA
N/C
N/C
183 199 €
N/C
N/C
79 974 €
N/C
N/C
N/C
Net margin
N/C
N/C
5.0%
N/C
N/C
1.7%
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE LUANGKHOT generates positive net income of 78 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 33 k€ -> 78 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
77 961 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 14%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 73%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
13.806%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
73.128%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
9.543
8.509
12.568
11.191
23.138
19.518
18.144
16.197
13.806
Financial autonomy
84.002
84.427
81.708
81.629
71.583
75.96
74.687
72.039
73.128
Repayment capacity
None
None
None
2.46
None
None
1.774
None
None
Cash flow / Revenue
None%
None%
None%
3.812%
None%
None%
7.047%
None%
None%
Sector positioning
Debt ratio
13.812025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Good
In 2025, the debt ratio of PHARMACIE LUANGKHOT (13.81) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
73.13%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Excellent
In 2025, the financial autonomy of PHARMACIE LUANGKHOT (73.1%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
1.77 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Good
In 2023, the repayment capacity of PHARMACIE LUANGKHOT (1.77) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 247.18. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
489.369
497.944
507.907
434.192
408.847
503.465
386.838
278.732
247.181
Interest coverage
None
None
None
4.02
None
None
0.854
None
None
Sector positioning
Liquidity ratio
247.182025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Good
In 2025, the liquidity ratio of PHARMACIE LUANGKHOT (247.18) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
0.85x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of PHARMACIE LUANGKHOT (0.8x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE LUANGKHOT
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
171 041 €
0 €
0 €
198 963 €
0 €
0 €
Inventory turnover (days)
0
0
0
28
0
0
32
0
0
Customer payment term (days)
0
0
0
5
0
0
5
0
0
Supplier payment term (days)
0
0
0
36
0
0
37
0
0
Positioning of PHARMACIE LUANGKHOT in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE LUANGKHOT is estimated at
1 238 419 €
(range 840 397€ - 1 943 251€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
840k€1238k€1943k€
1 238 419 €Range: 840 397€ - 1 943 251€
NAF 5 année 2025
Valuation method used
Net Income Multiple
77 961 €
×
15.9x
=1 238 420 €
Range: 840 397€ - 1 943 251€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE LUANGKHOT with other companies in the same sector:
Frequently asked questions about PHARMACIE LUANGKHOT
What is the revenue of PHARMACIE LUANGKHOT ?
The revenue of PHARMACIE LUANGKHOT in 2023 is 2.2 M€.
Is PHARMACIE LUANGKHOT profitable?
Yes, PHARMACIE LUANGKHOT generated a net profit of 78 k€ in 2025.
Where is the headquarters of PHARMACIE LUANGKHOT ?
The headquarters of PHARMACIE LUANGKHOT is located in CHASSE-SUR-RHONE (38670), in the department Isere.
Where to find the tax return of PHARMACIE LUANGKHOT ?
The tax return of PHARMACIE LUANGKHOT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE LUANGKHOT operate?
PHARMACIE LUANGKHOT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart